BioCardia, Inc.
BCDA
Rank in Stocks
#28390
BioCardia, Inc. is a pioneering clinical-stage company dedicated to... BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
Share Price
$0.9217
Last synced: 2026-11-11
Market Cap
$11.15M
Change (1 day)
-0.91%
Change (1 year)
-25.07%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BioCardia, Inc. (BCDA)
Category
Healthcare
Earnings for BioCardia, Inc. (BCDA)
Earnings in Jun 2026 TTM: $-7.34M
According to BioCardia, Inc.'s latest financial reports, its current earnings (TTM) are $-7.34M. In 2025 the company earned $-8.23M, a decrease compared to its 2024 earnings of $-7.95M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for BioCardia, Inc. from 2001 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-7.34M | -10.80% |
| 2025 | $-8.23M | 3.55% |
| 2024 | $-7.95M | -31.33% |
| 2023 | $-11.57M | -2.82% |
| 2022 | $-11.91M | -5.67% |
| 2021 | $-12.62M | -15.87% |
| 2020 | $-15.00M | 2.01% |
| 2019 | $-14.71M | 5.16% |
| 2018 | $-13.99M | 13.64% |
| 2017 | $-12.31M | 19.38% |
| 2016 | $-10.31M | -3,301.86% |
| 2015 | $322.00K | 37.61% |
| 2014 | $234.00K | 1,131.58% |
| 2013 | $19.00K | -105.74% |
| 2012 | $-331.00K | -47.63% |
| 2011 | $-632.00K | 13.67% |
| 2010 | $-556.00K | -89.05% |
| 2009 | $-5.08M | -10.16% |
| 2008 | $-5.65M | 1,925.81% |
| 2007 | $-279.00K | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | -100.00% |
| 2004 | $-723.00K | 50.63% |
| 2003 | $-480.00K | -60.88% |
| 2002 | $-1.23M | -37.43% |
| 2001 | $-1.96M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $4.76B | -64,952.16% |
US
|
|
| $-2.73B | 37,084.90% |
US
|
|
| $-4.02B | 54,624.03% |
AU
|
|
| $2.83B | -38,604.19% |
BE
|
|
| $1.50B | -20,497.09% |
NL
|
Questions about BioCardia, Inc.'s net income
What is BioCardia, Inc.'s net income?
BioCardia, Inc.'s net income over the last twelve months is $-7.34M, as of Jun 2026.
What was BioCardia, Inc.'s net income in 2025?
In 2025, BioCardia, Inc.'s net income was $-8.23M, compared with $-7.95M in 2024.
How has BioCardia, Inc.'s net income changed since 2020?
From 2020 to 2025, BioCardia, Inc.'s net income was highest in 2024 ($-7.95M) and lowest in 2020 ($-15.00M).
How does BioCardia, Inc.'s net income compare with similar companies?
BioCardia, Inc.'s net income ($-7.34M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.